Article
Medicine, General & Internal
Cristina Lopez, Birgit Burkhardt, John K. C. Chan, Lorenzo Leoncini, Sam M. Mbulaiteye, Martin D. Ogwang, Jackson Orem, Rosemary Rochford, Mark Roschewski, Reiner Siebert
Summary: Burkitt lymphoma (BL) is an aggressive B cell lymphoma affecting both children and adults. Research has identified key chromosomal aberrations, the role of MYC and Epstein-Barr virus in tumorigenesis. Differentiating between epidemiological variants of BL based on EBV status may better describe the biological heterogeneity of the disease. Diagnosis and treatment of BL vary between children and adults, with generally good outcomes observed in high-income countries.
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Oncology
Adam J. Olszewski, Lasse H. Jakobsen, Graham P. Collins, Kate Cwynarski, Veronika Bachanova, Kristie A. Blum, Kirsten M. Boughan, Mark Bower, Alessia Dalla Pria, Alexey Danilov, Kevin A. David, Catherine Diefenbach, Fredrik Ellin, Narendranath Epperla, Umar Farooq, Tatyana A. Feldman, Alina S. Gerrie, Deepa Jagadeesh, Manali Kamdar, Reem Karmali, Shireen Kassam, Vaishalee P. Kenkre, Nadia Khan, Seo-Hyun Kim, Andreas K. Klein, Izidore S. Lossos, Matthew A. Lunning, Peter Martin, Nicolas Martinez-Calle, Silvia Montoto, Seema Naik, Neil Palmisiano, David Peace, Elizabeth H. Phillips, Tycel J. Phillips, Craig A. Portell, Nishitha Reddy, Anna Santarsieri, Maryam Sarraf Yazdy, Knut B. Smeland, Scott E. Smith, Stephen D. Smith, Suchitra Sundaram, Adam S. Zayac, Xiao-Yin Zhang, Catherine Zhu, Chan Y. Cheah, Tarec C. El-Galaly, Andrew M. Evens
Summary: The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Editorial Material
Hematology
Mark Roschewski
Summary: This study highlights critical prognostic factors that impact outcomes in adult patients with Burkitt lymphoma in the United States.
Article
Oncology
Jeanne Bohler, Ulrike Bacher, Yara Banz, Raphael Stadelmann, Michael Medinger, Thilo Zander, Thomas Pabst
Summary: 20-40% of Burkitt lymphoma (BL) patients have relapsing or refractory (r/r) disease, and the standard treatment is not well-established. Blinatumomab, a bispecific T-cell engager, may be a potential treatment option for these patients. This retrospective multi-center case series investigated the use of blinatumomab in nine r/r BL patients, and found that it was safe and showed activity in some patients. This suggests that blinatumomab should be further explored as a treatment option for r/r BL.
Article
Hematology
Zeinab Afify, Manuela Orjuela-Grimm, Christine Moore Smith, Mansi Dalal, James B. Ford, Pallavi Pillai, Joanna M. Robles, Sonika Reddy, Sarah McCormack, Matthew J. Ehrhardt, Tonya Ureda, Warren Alperstein, Holly Edington, Tamara P. Miller, Jeremy D. Rubinstein, Madison Kavanaugh, Andrew J. Bukowinski, Erika Friehling, Julie M. Rivers, Karen M. Chisholm, Lianna J. Marks, Clinton C. Mason
Summary: PSOT-BL is a clinically aggressive malignancy and a rare form of PTLD. Most patients developed PSOT-BL more than 2 years after transplantation. Heart and liver were the most frequently transplanted organs. The outcomes of intensive regimens for PSOT-BL patients are comparable to immunocompetent children with BL. Multi-institutional collaboration is important for collecting prospective data to determine the optimal treatment regimen.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Hyokyoung G. Hong, Mateus H. Gouveia, Martin D. Ogwang, Patrick Kerchan, Steven J. Reynolds, Constance N. Tenge, Pamela A. Were, Robert T. Kuremu, Walter N. Wekesa, Nestory Masalu, Esther Kawira, Tobias Kinyera, Xunde Wang, Jiefu Zhou, Thiago Peixoto Leal, Isaac Otim, Ismail D. Legason, Hadijah Nabalende, Herry Dhudha, Mediatrix Mumia, Francine S. Baker, Temiloluwa Okusolubo, Leona W. Ayers, Kishor Bhatia, James J. Goedert, Joshua Woo, Michelle Manning, Nathan Cole, Wen Luo, Belynda Hicks, George Chagaluka, W. Thomas Johnston, Nora Mutalima, Eric Borgstein, George N. Liomba, Steve Kamiza, Nyengo Mkandawire, Collins Mitambo, Elizabeth M. Molyneux, Robert Newton, Amy Hutchinson, Meredith Yeager, Adebowale A. Adeyemo, Swee Lay Thein, Charles N. Rotimi, Stephen J. Chanock, Ludmila Prokunina-Olsson, Sam M. Mbulaiteye
Summary: This study investigated the association between Plasmodium falciparum infection and Burkitt lymphoma (BL) risk. The results showed that the HBB-rs334(T) variant, which protects against malaria, was associated with lower risk of both P. falciparum infection and BL. The ABO-rs8176703(T) variant was associated with decreased risk of BL but not P. falciparum infection. These findings increase support for the etiological correlation between P. falciparum and BL risk.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Francine S. Baker, Jeanny Wang, Oscar Florez-Vargas, Nathan R. Brand, Martin D. Ogwang, Patrick Kerchan, Steven J. Reynolds, Constance N. Tenge, Pamela A. Were, Robert T. Kuremu, Walter N. Wekesa, Nestory Masalu, Esther Kawira, Tobias Kinyera, Isaac Otim, Ismail D. Legason, Hadijah Nabalende, George Chagaluka, Nora Mutalima, Eric Borgstein, George N. Liomba, Steve Kamiza, Nyengo Mkandawire, Collins Mitambo, Elizabeth M. Molyneux, Robert Newton, Ludmila Prokunina-Olsson, Sam M. Mbulaiteye
Summary: This study found no significant association between three coding genetic variants within IFNL4 and the risk of Burkitt lymphoma (BL). However, considering that BL occurs in children who survived early childhood infections, future studies should explore the associations of IFNL4-dG allele in younger children.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
(2023)
Article
Veterinary Sciences
Luca Aresu, Chiara Agnoli, Arturo Nicoletti, Antonella Fanelli, Valeria Martini, Francesco Bertoni, Laura Marconato
Summary: Canine Burkitt-like lymphoma (B-LL) is a rare tumor in dogs classified as a high-grade B-cell malignancy. Compared to the human counterpart, phenotypical differences are observed, and despite treatment, prognosis remains poor. However, around 30% of dogs can survive more than 1 year.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Oncology
Zhao Wang, Meiting Chen, Xiaojie Fang, Huangming Hong, Yuyi Yao, He Huang
Summary: Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin's lymphoma, and the high expression of KIF15 in BL is closely related to its development. Knockdown of KIF15 can inhibit proliferation and migration, promote cell apoptosis, and arrest the cell cycle in BL cells.
CANCER CELL INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Birgit Burkhardt, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp Berning, Katrin Reutter, Marius Rohde, Arndt Borkhardt, Thomas Burmeister, Sandeep Dave, Alexandar Tzankov, Martin Dugas, Sarah Sandmann, Falko Fend, Jasmin Finger, Stephanie Mueller, Nicola Goekbuget, Torsten Haferlach, Wolfgang Kern, Wolfgang Hartmann, Wolfram Klapper, Ilske Oschlies, Julia Richter, Udo Kontny, Mathias Lutz, Britta Maecker-Kolhoff, German Ott, Andreas Rosenwald, Reiner Siebert, Arend von Stackelberg, Brigitte Strahm, Wilhelm Woessmann, Martin Zimmermann, Myroslav Zapukhlyak, Michael Grau, Georg Lenz
Summary: This study compares mutational profiles in different age groups of Burkitt lymphoma patients and finds a transition in mutational features between the ages of 25 and 40. There are also differences in the mutation frequencies between pediatric and adult patients. TP53 mutations in pediatric patients are significantly associated with higher relapse incidence.
NATURE COMMUNICATIONS
(2022)
Article
Hematology
Anne C. Wilke, Carmen Doebele, Alena Zindel, Kwang Seok Lee, Sara A. Rieke, Michele Ceribelli, Federico Comoglio, James D. Phelan, James Q. Wang, Yana Pikman, Dominique Jahn, Bjoern Haeupl, Constanze Schneider, Sebastian Scheich, Frances A. Tosto, Hanibal Bohnenberger, Philipp Stauder, Frank Schnuetgen, Mikolaj Slabicki, Zana A. Coulibaly, Sebastian Wolf, Kamil Bojarczuk, Bjoern Chapuy, Christian H. Brandts, Philipp Stroebel, Caroline A. Lewis, Michael Engelke, Xincheng Xu, Hahn Kim, Thanh Hung Dang, Roland Schmitz, Daniel J. Hodson, Kimberly Stegmaier, Henning Urlaub, Hubert Serve, Clemens A. Schmitt, Fernando Kreuz, Gero Knittel, Joshua D. Rabinowitz, Hans Christian Reinhardt, Matthew G. Vander Heiden, Craig Thomas, Louis M. Staudt, Thorsten Zenz, Thomas Oellerich
Summary: This study identified vulnerabilities in Burkitt lymphoma (BL) through genome-scale CRISPR-Cas9 screens and validated serine hydroxymethyltransferase 2 (SHMT2) as a potential drug target. Mechanistically, SHMT2 inhibition disrupted the oncogenic transcription factor TCF3 and collapsed tonic BCR signaling, providing new perspectives for innovative therapies.
Article
Oncology
Semjon Sidorov, Lara Fux, Katja Steiner, Samyo Bounlom, Sabrina Traxel, Tarik Azzi, Arbeneshe Berisha, Christoph Berger, Michele Bernasconi, Felix K. Niggli, Yvonne Perner, Sugeshnee Pather, Werner Kempf, David Nadal, Simone Burgler
Summary: The study reveals the dichotomous effects of CD4 + T cells in endemic Burkitt lymphoma, suggesting that they may suppress cancer development by killing pre-cancerous cells without specific translocations, but also indirectly promote cancer progression by inducing EBV latency switching. Moreover, it demonstrates how CD4 + T cells can impact cancer pathogenesis and progression, providing a new in vitro model for further research on the role of IgH/c-myc translocations.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Hematology
Nicole Thomas, Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton, Jeremy S. Abramson, Richard F. Ambinder, Stefan Barta, Nancy L. Bartlett, Jeffrey Bethony, Kishor Bhatia, Jay Bowen, Anthony C. Bryan, Ethel Cesarman, Corey Casper, Amy Chadburn, Manuela Cruz, Dirk P. Dittmer, Maureen A. Dyer, Pedro Farinha, Julie M. Gastier-Foster, Alina S. Gerrie, Bruno M. Grande, Timothy Greiner, Nicholas B. Griner, Thomas G. Gross, Nancy L. Harris, John D. Irvin, Elaine S. Jaffe, David Henry, Rebecca Huppi, Fabio E. Leal, Michael S. Lee, Jean Paul Martin, Marie-Reine Martin, Sam M. Mbulaiteye, Ronald Mitsuyasu, Vivian Morris, Charles G. Mullighan, Andrew J. Mungall, Karen Mungall, Innocent Mutyaba, Mostafa Nokta, Constance Namirembe, Ariela Noy, Martin D. Ogwang, Abraham Omoding, Jackson Orem, German Ott, Hilary Petrello, Stefania Pittaluga, James D. Phelan, Juan Carlos Ramos, Lee Ratner, Steven J. Reynolds, Paul G. Rubinstein, Gerhard Sissolak, Graham Slack, Shaghayegh Soudi, Steven H. Swerdlow, Alexandra Traverse-Glehen, Wyndham H. Wilson, Jasper Wong, Robert Yarchoan, Jean C. ZenKlusen, Marco A. Marra, Louis M. Staudt, David W. Scott, Ryan D. Merin
Summary: By sequencing the whole genome of 230 Burkitt lymphoma (BL) and 295 diffuse large B-cell lymphoma (DLBCL) tumors, additional significantly mutated genes were identified, new subtypes of BL and DLBCL were discovered, and genetic features associated with patient outcomes were determined. These findings highlight the shared pathogenesis between adult BL and pediatric BL, and provide a new framework for epidemiology, diagnosis, and therapeutic strategies.
Article
Oncology
Irene Bagaloni, Axel Visani, Sara Biagiotti, Annamaria Ruzzo, Mohsen Navari, Maryam Etebari, Lucia Mundo, Massimo Granai, Stefano Lazzi, Alessandro Isidori, Federica Loscocco, Jiejin Li, Lorenzo Leoncini, Giuseppe Visani, Mauro Magnani, Pier Paolo Piccaluga
Summary: The study revealed enhanced glucose metabolism in most lymphoma subtypes, with a general shift to aerobic glycolysis. Not only aggressive lymphomas, but also indolent ones like marginal zone lymphomas, showed this phenomenon. Metformin was shown to induce cell death in BL cells by affecting cellular metabolism.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Li Huang, Can Meng, Dan Liu, Xiang-Jun Fu
Summary: This case report describes a rare occurrence of secondary peripheral T-cell lymphoma and AML after Burkitt lymphoma treatment in a 54-year-old female patient. The patient achieved complete remission after initial treatment, but later developed lymphadenectasis, gastrointestinal invasion, and AML. The patient's condition deteriorated rapidly, leading to critical illness and discharge from the hospital.
WORLD JOURNAL OF CLINICAL CASES
(2021)